Contraceptive Patch

Products

Two contraceptive patches are currently on the market in many countries. They are transdermal patches:

Unlike the Evra patch (20 cm2), the new Lisvy patch is smaller (11 cm2) and transparent instead of skin-colored. Thus, the application of Lisvy is more discreet.

Structure and properties

Norelgestromin and gestodene are progestins. Ethinylestradiol is an estrogen derived from estradiol.

Effects

The combination of the two active ingredients has contraceptive properties. The effects are primarily due to inhibition of ovulation. Thickening of cervical secretions, inhibition of egg implantation, and alteration of fallopian tube movements are also involved in the effects. The patch continuously releases the active ingredients through the skin into the bloodstream.

Indications

For hormonal contraception.

Dosage

According to the professional information. The patch is worn for three consecutive weeks. One patch is applied at a time for seven days. The three weeks are followed by a one-week break before administration is started again. Carefully follow the instructions in the package insert. See also under Administering TTS.

Contraindications

Numerous precautions should be observed when using hormonal contraceptives. For complete details, see the drug label.

Interactions

Like other steroids, the active ingredients are metabolized by CYP3A4. Corresponding drug-drug interactions with CYP inducers and inhibitors are possible. Inducers may reduce contraceptive efficacy and lead to unplanned pregnancy.

Adverse effects

The most common possible adverse effects include:

  • Reactions at the site of administration
  • Emotional lability
  • Headaches, migraines
  • Nausea, vomiting
  • Bleeding
  • Painful breasts
  • Headache

Very rarely, serious side effects such as venous thromboembolic events, arterial thrombosis, myocardial infarction, liver tumors, breast cancer, and cervical cancer are possible.